Video

Neoadjuvant Chemotherapy as Standard-of-Care for Muscle-Invasive Urothelial Carcinoma

Author(s):

Jeanny B. Aragon-Ching, MD, FACPSrikala Sridhar, MD, MSc, FRCPC

Srikala Sridhar, MD, MSc, FRCPC, explains the importance of neoadjuvant cisplatin-based chemotherapy and why bladder-sparing treatments should be considered for all patient populations.

Related Videos
Vikram M. Narayan, MD
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Nikhil Gopal, MD, assistant professor, urology, College of Medicine, Memphis Department of Urology, The University of Tennessee Health Science Center
Jonathan E. Rosenberg, MD
Joaquim Bellmunt, MD, PhD
Arlene O. Siefker-Radtke, MD
Related Content
3d rendered illustration - bladder cancer: © Sebastian Kaulitzki - stock.adobe.com
June 1st 2024

Neoadjuvant Sacituzumab Govitecan Displays Activity in Muscle-Invasive Bladder Cancer, But Questions Remain

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Vikram M. Narayan, MD, of Emory University Hospital
May 23rd 2024

Narayan Discusses Bladder Preservation and the Role of Gene Therapies in NMIBC

Terence Friedlander, MD
April 24th 2023

FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

Peter H. O'Donnell, MD, of University of Chicago
May 22nd 2024

Expansion of Frontline Immunotherapy Regimens Improves Prognosis, Increases Optimism in Urothelial Cancer

Vikram M. Narayan, MD, Emory University Hospital; director, urological oncology, Grady Memorial Hospital; assistant professor, Department of Urology, Emory University School of Medicine; member, Winship Cancer Institute
May 15th 2024

Nadofaragene Firadenovec Sets the Stage for Gene Therapies in NMIBC